Healthcare Industry News: AbVitro
News Release - October 23, 2014
AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive OfficerBOSTON, Oct. 23, 2014 -- (Healthcare Sales & Marketing Network) -- AbVitro Inc., a therapeutic target discovery company, announced that Jeffrey M. Ostrove, Ph.D. has been appointed as chief executive officer and director of the Company. Dr. Ostrove brings a strong background of both business and product development experience to the AbVitro team.
"AbVitro's immune sequencing technology is an incredibility powerful platform for use in target and drug discovery, and I am very excited to have this opportunity to work with such a great team of scientists who are leading the field in this area. The platform has uses in so many different clinical disciplines and should allow us to partner with a broad range of companies across multiple disease areas," noted Dr. Ostrove.
Prior to joining AbVitro, Dr. Ostrove was the founding president and chief executive officer of Ceregene, Inc., a clinical stage company developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Ceregene was sold to Sangamo BioSciences. Prior to joining Ceregene, Dr. Ostrove was chief operating officer of NeuroVir Therapeutics, Inc. located in Vancouver, B.C. and San Diego, CA and was instrumental in its merger with Medigene AG. Preceding NeuroVir (Medigene), Dr. Ostrove served as senior vice president and chief scientist of MAGENTA Corporation of Rockville, Maryland, a company he founded as a subsidiary of BioReliance, Inc. where he was also vice president of scientific development. Dr. Ostrove also served on the staff of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Dr. Ostrove holds a Ph.D. in molecular biology from the University of Florida College of Medicine, and completed his post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Ostrove is also a past member of the board of directors of the Biotechnology Industry Organization (BIO).
AbVitro is a therapeutic target discovery company, with a unique technology platform that leverages natural immune responses to address diseases with unmet medical needs. Based on technology developed by the visionary George Church at Harvard Medical School, AbVitro's technology allows for the identification of complete, natively paired B cell antibodies and T cell receptors across millions of single cells at unprecedented resolution. This high-throughput single-cell immune sequencing technology is then used to identify novel therapeutic targets and antibodies to cancer, autoimmune and infectious diseases, as well as utility in any disorder that has an immune component.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.